Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhangzhou
Clinical trial register · China

Clinical Trials in Zhangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Capital Medical University7 Fujian Provincial Hospital3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Akeso2 Bristol-Myers Squibb2
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Zhangzhou

44 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Fujian Medical University Union Hospital
Observational
2,000
Fuzhou, Zhangzhou, Lanzhou, Mudanjiang, Liaocheng, Shanghai
2027-04-01
Recruiting
Hua Huang, MD, PhD
Phase 3
170
Beijing, Chongqing, Zhangzhou, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang
2026-12-01
Not yet open
First Hospital of China Medical University
Observational
2,400
Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Tianshui, Guangzhou, Shantou
2026-11-01
Not yet open
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
NCT07894315Ischemic Stroke, Post-stroke Dysphagia, Swallowing Disorders
First Affiliated Hospital of Fujian Medical University
Not applicable
60
Fuzhou, Zhangzhou, Zhengzhou, Xi'an, Beijing
2026-11
Not yet open
First Affiliated Hospital of Fujian Medical University
Phase 2
30
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
2026-08-01
Not yet open
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)
NCT07668960High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection
Shanghai Mianyi Biopharmaceutical Co., Ltd.
Phase 1/2
60
Beijing, Chongqing, Zhangzhou, Jinan
2026-06-17
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Active, closed
Capital Medical University
Phase 1
92
Zhangzhou, Jiuquan, Yulin, Shangqiu, Xuzhou, Beijing, Zibo, Huzhou
2026-04-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
800
Chizhou, Hefei, Chongqing, Zhangzhou, Lanzhou, Foshan, Shenzhen, Guiyang
2026-04-14
Recruiting
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Recruiting
Fujian Cancer Hospital
Phase 2
89
Fuzhou, Zhangzhou, Guangzhou, Nanning, Hohhot, Dalian, Jinan, Jining
2026-01-28
Active, closed
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
Recruiting
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Recruiting
Xuanwu Hospital, Beijing
Not applicable
364
Fuzhou, Zhangzhou, Beijing
2025-10-12
Recruiting
Capital Medical University
Not applicable
240
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Active, closed
Capital Medical University
Not applicable
438
Ma’anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-04
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
666
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2025-09
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
NCT06811844Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
The First Affiliated Hospital of Xiamen University
Phase 2
208
Xiamen, Zhangzhou, Haikou
2025-02-25
Recruiting
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
NCT06761027Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
DrugsAnlotinib·Sintilimab
Fujian Provincial Hospital
Phase 1/2
29
Fuzhou, Zhangzhou
2024-12-23
Recruiting
Capital Medical University
Phase 3
1,500
Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou
2024-12-13
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Active, closed
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Neoadjuvant Triple Therapy for Resectable HCC
NCT06569498Resectable Hepatocellular Carcinoma
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning
2024-09-23
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
99
Hefei, Fuzhou, Quanzhou, Xiamen, Zhangzhou, Shanghai, Hangzhou
2024-09-11
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Recruiting
Peking Union Medical College Hospital
Observational
1,000
Wuhu, Beijing, Zhangzhou, Zunyi, Chifeng, Hohhot
2024-08-02
Recruiting
Tingyu-Yi
Not applicable
100
Zhangzhou
2024-01-30
Not yet open
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage
NCT06670456Stroke, Acute, Intracerebral Hemorrhage
De-zhi Kang
Observational
3,000
Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng
2023-11-06
Recruiting
A Clinical Study on Using Multimodal Ultrasound to Assess Muscle Mass in Metabolic Diseases
NCT07836088Metabolic Syndrome, Obesity, Sarcopenia, Type 2 Diabetes
Zhangzhou Municipal Hospital
Observational
320
Zhangzhou
2023-07-01
Active, closed
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038Basilar Artery Occlusion, Endovascular Treatment
Beijing Tiantan Hospital
Not applicable
338
Hefei, Beijing, Anyang, Zhangzhou, Baotou
2022-11-07
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
DrugSonrotoclax
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Observational
160
Zhangzhou, Shanghai
2022-01-01
Active, closed
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
DrugVedolizumab
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/zhangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies with a site in Zhangzhou.

How many clinical trials are recruiting in Zhangzhou?

27 of the 44 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 8 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhangzhou), 44 studies
PhaseStudiesRecruitingShare
Phase 316836.4%
Not applicable9620.5%
Observational8618.2%
Phase 27515.9%
Phase 1/2326.8%
Phase 1102.3%

Most active sponsors

Lead sponsors with the most studies (Zhangzhou)
Lead sponsorStudiesRecruiting
Capital Medical University73
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.31
Fujian Provincial Hospital33
Akeso21
Bristol-Myers Squibb21
First Affiliated Hospital of Fujian Medical University20
Fujian Medical University Union Hospital21
BeiGene10
Beijing Anzhen Hospital11
Beijing Tiantan Hospital10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.